--- title: Why the Adderall Shortage Has Lasted So Long description: The Adderall shortage has lasted at least six months. Here's why it's still so hard to get Adderall and other amphetamine mixed salts. canonical: https://time.com/6272668/adderall-shortage-update/ author: Jamie Ducharme article:opinion: false article:content_tier: free article:published_time: 2023-04-18T15:39:51.000Z article:modified_time: 2026-08-04T07:51:17.138Z article:section: Health og:title: Why the Adderall Shortage Has Lasted So Long og:description: Ending a drug shortage is more complex than it seems og:url: https://time.com/6272668/adderall-shortage-update/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltaa259b02869db432/698a3c18457a52cfd1d6781d/pill-bottles.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 5616 og:image:height: 3159 og:image:alt: Dozens of prescription pill bottles og:type: article twitter:card: summary_large_image twitter:title: Why the Adderall Shortage Has Lasted So Long twitter:description: Ending a drug shortage is more complex than it seems twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltaa259b02869db432/698a3c18457a52cfd1d6781d/pill-bottles.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Why the Adderall Shortage Has Lasted So Long > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=4dd1db04-d929-4394-ba78-2c23fec97339&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Daily | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=4dd1db04-d929-4394-ba78-2c23fec97339&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=4dd1db04-d929-4394-ba78-2c23fec97339&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ## Video: White House Addresses Texas Court Ruling Threatening Availability of Drug Used in Medication Abortions [Watch (HLS stream): White House Addresses Texas Court Ruling Threatening Availability of Drug Used in Medication Abortions](https://cdn.jwplayer.com/manifests/hWcQOKB4.m3u8) (1:00)  _Published 2023-04-10. There is uncertainty about access to the most commonly used method of abortion in the United States following two separate and conflicting court rulings in Texas and Washington over the legality of mifepristone. Kacsmaryk’s decision ordering a hold on federal approval of mifepristone overruled decades of scientific approval._  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Apr 18, 2023 3:39 PM UTC  Dozens of prescription medicine bottles in a jumble. This collection of pill bottles is symbolic of the many medications senior adults and chronically ill people take. Dozens of prescription medicine bottles in a jumble. This collection of pill bottles is symbolic of the many medications senior adults and chronically ill people take. Getty Images  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Apr 18, 2023 3:39 PM UTC In October 2022, the U.S. Food and Drug Administration (FDA) [announced a shortage](https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-shortage-adderall) of amphetamine mixed salts—a drug category that includes Adderall, the stimulant medication often used to treat [attention-deficit/hyperactivity disorder](https://time.com/6211695/adhd-tiktok-women/) (ADHD). In the six months since, little has changed. Numerous amphetamine mixed salts products are still in short supply, although certain manufacturers expect to release additional inventory in April or May, according to an Apr. 10 [update](https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=857&loginreturnUrl=SSOCheckOnly) to the American Society of Health-System Pharmacists’ (ASHP) drug shortage database. Half a year may seem like ample time to get more of a medication into production and circulation. But experts say ending a drug shortage is more complex than it seems—particularly when it comes to a heavily regulated substance like Adderall. “Six months feels like a long time, and it absolutely is a long time for patients,” says Emily Tucker, an assistant professor of industrial engineering at Clemson University who studies drug shortages. “But in the broader context of the pharma industry, it’s very common to see shortages of over a year.” Drug shortages are usually caused by manufacturing disruptions, Tucker says. When the FDA announced the Adderall shortage last year, it pointed to “ongoing intermittent manufacturing delays” at Teva Pharmaceuticals, a major supplier of Adderall. But increasing demand seems to be a big factor, too. [ADHD diagnoses and stimulant prescriptions are on the rise](https://time.com/6271049/adhd-diagnoses-rising/), apparently driven partially by [relaxed prescribing standards during the pandemic](https://time.com/6225361/telehealth-startups-cerebral-done-ahead/) and partially by better awareness and detection of the condition. That spike in demand seems to be constraining the available medication supply. **Read More**: [_If You’re Feeling Anxious, Try This 2,000-Year-Old, Neuroscience-Backed Hack_](https://time.com/6114215/if-youre-feeling-anxious-try-this-2000-year-old-neuroscience-backed-hack/) On the surface, that seems like an easier problem to fix: if more people need a drug, simply make more of it. But “even if everyone wants to increase the production, it might just not be possible,” says Ozlem Ergun, a professor of mechanical and industrial engineering at Northeastern University and an expert in pharmaceutical supply chains. Drug manufacturing is a multi-step process, explains Philip Almeter, chief pharmacy officer at UK HealthCare in Kentucky. Typically, different manufacturers are involved in first processing a drug’s active ingredients, then putting on finishes touches before it hits pharmacy shelves. “It’s not as simple as just making more,” Almeter says. “You have to make more at different levels.” --- ### More from TIME --- Many pharmaceutical manufacturing plants also operate at near-peak capacity and make multiple drugs under the same roof. Scaling up production of one drug could require ceasing or reducing production of another drug, leading to a domino effect, Ergun explains. “It’s not as easy as, ‘Why don’t you just go and jack up your manufacturing?’” she says. Adderall is also a special case because it’s a controlled substance. Due to its potential for illicit sale and use, production is regulated by the U.S. Drug Enforcement Administration (DEA) as well as the FDA. To avoid having more of the drug in circulation than necessary, the DEA caps the amount of amphetamine available to manufacturers in a given year. Authorized manufacturers apply to receive a portion of the total supply and can request more if necessary, but the DEA may deny a request if the total quota has already been met, among other reasons. Camber, a pharmaceutical company that makes amphetamine mixed salts, says it is waiting for the DEA to review its quota application, according to the [ASHP’s drug shortage database](https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=857). Teva representatives have also suggested that the DEA’s quota system is contributing to the ongoing shortage, _Bloomberg_ [reports](https://www.bloomberg.com/news/newsletters/2023-02-28/are-adderall-dea-quotas-contributing-to-the-shortage). (Neither company responded to comment requests by press time.) **Read More**: [_How to Be Mindful if You Hate Meditating_](https://time.com/6249527/how-to-be-mindful-hate-meditating/) The DEA, however, has said otherwise. A representative for the DEA declined to comment for this story but highlighted a December 2022 [entry in the Federal Register](https://www.federalregister.gov/documents/2022/12/02/2022-26351/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment#:~:text=According%20to%20DEA's%20data%2C%20manufacturers,for%20amphetamine%20at%20this%20timehttps://www.federalregister.gov/documents/2022/12/02/2022-26351/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment), which says U.S. manufacturers did not use the total allotted amphetamine supply in 2020, 2021, or 2022\. “The majority of the manufacturers contacted by DEA and/or FDA have responded that they currently have sufficient quota to meet their contracted production quantities for legitimate patient medical needs,” it says. As a result, the DEA did not increase the quota for 2023, but maintains the authority to do so if necessary. There’s so little transparency in the pharmaceutical industry that it’s difficult to know the real story behind the back-and-forth, Tucker says. Drug makers don’t need to publicly share much information about where their drugs are made and sourced, how much of them they make, or their overall production capacities. The DEA, meanwhile, doesn’t need to share all the details about how much of the amphetamine quota each company receives. That opaque system makes it hard to know exactly what’s causing a shortage. “It’s very hard to correct a system when you don’t know what’s going on in the system,” Ergun says. She contributed to [a recent report](https://nap.nationalacademies.org/resource/26420/interactive/) on improving medical supply chains for the National Academies of Science, Engineering, and Medicine, and one of its primary recommendations was increased transparency in the industry. Without freer-flowing information, Tucker says there’s no telling when shortages will let up, though she’s encouraged that some manufacturers expect additional supplies this spring. The amount of media attention and public outcry about the Adderall shortage may also help resolve it relatively quickly, she says—which isn’t the case for many of the [160 drugs with reported shortages](https://www.ashp.org/drug-shortages/shortage-resources/drug-shortages-statistics) in the U.S. last year. Those “are also a big deal,” Tucker says. “But perhaps they’re not getting this degree of attention.” ## Transcript Once again, today the president has called on republicans in Congress to work together with Democrats, to take action over the weekend. A single Court. In Texas has taken the dangerous steps of rejecting FDA, scientific approval of me for Prestone, a medication that has been on the market for more than 20 years and is used safely in more than 60 countries, providing Critical Care for Women. This court decision threatens access to to this medication which is used not only for abortion, but also for other critical person purposes like helping women manage miscarriages. If the decision stands, it will put Women's Health at risk and undermined, the fda's ability to ensure patients have access to safe and effective medications, when they need them. The most, this decision, further Stripes away, Americans fundamental freedoms, and interferes with a woman's ability to make decisions about her own body. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6272668/adderall-shortage-update/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6272668/adderall-shortage-update/"},"headline":"Why the Adderall Shortage Has Lasted So Long","datePublished":"2023-04-18T15:39:51.000Z","dateModified":"2026-08-04T07:51:17.138Z","description":"Ending a drug shortage is more complex than it seems.","url":"https://time.com/6272668/adderall-shortage-update/","keywords":["Drugs","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/bltaa259b02869db432/698a3c18457a52cfd1d6781d/pill-bottles.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Jamie Ducharme","jobTitle":"Ducharme is a contributor to TIME.","url":"https://time.com/author/jamie-ducharme/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/bltaa259b02869db432/698a3c18457a52cfd1d6781d/pill-bottles.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Dozens of prescription pill bottles","caption":"Dozens of prescription pill bottles","creditText":"Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/drugs/","name":"Drugs"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6272668/adderall-shortage-update/","name":"Why the Adderall Shortage Has Lasted So Long"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"White House Addresses Texas Court Ruling Threatening Availability of Drug Used in Medication Abortions","description":"There is uncertainty about access to the most commonly used method of abortion in the United States following two separate and conflicting court rulings in Texas and Washington over the legality of mifepristone. Kacsmaryk’s decision ordering a hold on federal approval of mifepristone overruled decades of scientific approval.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/hWcQOKB4/poster.jpg?width=720","uploadDate":"2023-04-10T19:11:29.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/hWcQOKB4.m3u8","embedUrl":"https://time.com/6272668/adderall-shortage-update/","duration":"PT1M","potentialAction":{"@type":"SeekToAction","target":"https://time.com/6272668/adderall-shortage-update/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}] ```